Loading...
XTAE
NXTG
Market cap9mUSD
Oct 30, Last price  
36.10ILS
1D
3.14%
1Q
-5.50%
Jan 2017
-98.21%
Name

Nextage Therapeutics Ltd

Chart & performance

D1W1MN
XTAE:NXTG chart
P/E
—
P/S
8.13
EPS
—
Vol. 1Y
126.15%
Shs. 5Y
29.61%
Rev. 5Y
79.89%
Div Yld LY
—
Div Yld TTM
—
Revenues
4m
+771.19%
28,000405,000383,000297,000191,00091,0000876,000413,0003,598,000
Net income
-6m
L+84.65%
-8,746,000-5,732,000-8,735,000-2,110,000-15,966,000-7,728,000-5,985,000-3,879,000-3,283,000-6,062,000
CFO
-7m
L+741.76%
-6,998,000-5,671,000-4,952,000-5,005,000-7,186,000-2,409,000-6,012,000-2,262,000-795,000-6,692,000
Dividend
Jun 09, 200368000 ILS/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Nextage Therapeutics Ltd, a pharmaceutical company, develops cannabinoid-based products in Israel and internationally. The company was incorporated in 1982 and is based in Ness Ziona, Israel.

Key people

Meir Yoeli
Chief Executive Officer · since 2019
Yifftach Biel
Deputy Vice President - Finance · since 2019
Doron Debbie
Independent Director · since 2019
URL
https://m-medic.com/
IPO date
Jan 01, 1993
Employees
42
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT